Sonelokimab is a monoclonal antibody commercialized by MoonLake Immunotherapeutics, with a leading Phase II program in Psoriatic Arthritis. According to Globaldata, it is involved in 10 clinical trials, of which 5 were completed, 2 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Sonelokimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Sonelokimab is expected to reach an annual total of $1.09 bn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sonelokimab Overview
Sonelokimab (M-1095) is under development for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis(r-axSpA) and hidradenitis suppurativa. The drug candidate is administered subcutaneously. M1095 is a trivalent bi-specific nanobody that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F. The drug candidate is developed on basis of nanobody technology. It was also under development for rheumatoid arthritis.
See Also:
MoonLake Immunotherapeutics Overview
MoonLake Immunotherapeutics (MoonLake), formerly Helix Acquisition, is a biopharmaceutical company that develops and markets medicines for immunologic diseases for the treatment of inflammatory skin and joint diseases. The company is headquartered in Zug, Switzerland.
The operating loss of the company was US$65.1 million in FY2022, compared to an operating loss of US$53.6 million in FY2021. The net loss of the company was US$50 million in FY2022, compared to a net loss of US$53.6 million in FY2021.
For a complete picture of Sonelokimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.